Hodgkin disease in children: Results of a prospective randomized trial in a single institution in Argentina

Sackmann‐Muriel, Federico; Zubizarreta, Pedro; Gallo, Guillermo; Scopinaro, Marcelo; Alderete, Daniel; Alfaro, Elizabeth M.; Casak, Sandra J.; Chantada, Guillermo; Felice, Marı́a Sara; Quinteros, Rubén

doi:10.1002/(sici)1096-911x(199712)29:6<544::aid-mpo5>3.3.co;2-a

Cited by 5 publications

(7 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Some studies in developing countries also show a low age at onset of HL in children [2,4,5]. In our study, 15% of the patients were 5 years old or less, and 46% were under 10 years.…”

Section: Discussionsupporting

confidence: 59%

“…3 Overall survival and relapse-free survival according to stages reported in developed countries (more than 70%) [16,18,23,24]. A predominance of the mixed cellularity type has been reported in many other developing countries [2,4,5,7]. These two aspects, low age and a high prevalence of the mixed cellularity subtype, suggest a role of EBV in childhood HL in developing countries [25,26].…”

Section: Discussionmentioning

confidence: 96%

“…In developing countries, however, this goal has not been achieved. The few reports on the management of HL amongst children in developing countries [2][3][4][5][6][7][8][9] show some epidemiological and clinicopathological differences (e.g. in age, histological subtype and distribution) from similar cases in developed countries.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Lymphome de Hodgkin de l’enfant: expérience de 24 ans au service d’hématologie à Casablanca, Maroc

et al. 2009

View full text Add to dashboard Cite

Background: More than 90% of children with Hodgkin lymphoma (HL) can be cured with current treatment modalities. This goal has not, however, been reached in most developing countries. We report here the results of a retrospective study of 24 years' experience in the management of HL in children in one institution in Morocco. Procedure: All cases of histologically confirmed HL in children under 17 years of age seen in our department between 1978 and 2001 were included in this study. The treatment modality varied during the 24-year period but mainly comprised combined chemotherapy and radiation therapy. Results: Two hundred and three patients were included. The mean age of the patients was 10.3 years, and 46% were 10 years old or less. The male:female ratio was 2.9. The mean duration of symptoms before diagnosis was 10.4 months. Lukes-Rye histological types 2 and 3 predominated, representing 40% and 37% of cases, respectively. Advanced stages III and IV represented 55.5% of the cases. After a median follow-up of 10 years, only 134 patients were available for evaluation. The 10-year overall and relapse-free survival rates were 64% and 58%, respectively. Conclusion: The results for this large series of cases of childhood HL in Morocco are similar to those observed in other developing countries. Steps must be taken, however, to reduce the numbers who abandon treatment and to improve the therapeutic results.Keywords Children · Hodgkin lymphoma · Developing country Résumé Contexte : Plus de 90 % des enfants atteints de Lymphome de Hodgkin (LH) peuvent actuellement être guéris. Malheureusement, dans les pays en voie de développement, le taux de guérison de ces patients reste en deçà des résultats rapportés dans les pays développés. Nous rapportons dans une série rétrospective, notre expérience de 24 ans dans la prise en charge d'enfants atteints de LH. Matériels et Méthodes : Tous les patients âgés de moins de 17 ans atteints de LH histologiquement prouvé ont été inclus dans cette étude entre 1978 et 2001. Les modalités thérapeutiques ont varié durant cette période mais étaient essentiellement basées sur l'association chimiothérapie et radiothérapie. Résultats : Deux cent trois patients ont été inclus. L'âge médian des patients est de 10.3 ans et 46 % des patients étaient âgés de 10 ans et moins. Le sex-ratio M/F était de 2.9. La durée des symptômes avant le diagnostic était de 10.4 mois. Les types histologiques 2 et 3 selon la classification de Lukes-Rye prédominaient avec respectivement 40 % et 37 % des cas. Les stages avancés III et IV représentaient 55 %. Après un suivi médian de 10 ans, 134 patients seulement étaient évaluables. La survie globale et la survie sans rechute à 10 ans étaient de 64 % et 58 % respectivement.Conclusion : Les résultats rapportés dans notre série sont similaires à ceux rapportés dans plusieurs études émanant de pays en voie de développement. Des efforts restent à fournir afin de réduire le taux de patients perdus de vue et d'améliorer les résultats thérapeutiques.

show abstract

“…Some studies in developing countries also show a low age at onset of HL in children [2,4,5]. In our study, 15% of the patients were 5 years old or less, and 46% were under 10 years.…”

Section: Discussionsupporting

confidence: 59%

Section: Discussionmentioning

confidence: 96%

See 1 more Smart Citation

Lymphome de Hodgkin de l’enfant: expérience de 24 ans au service d’hématologie à Casablanca, Maroc

et al. 2009

View full text Add to dashboard Cite

show abstract

“…All other patients with partially resected or unresectable stage IA disease or stage IIA disease will receive a non‐intensive combination chemotherapy regimen comprising cyclophosphamide (500 mg/m 2 , day 1), vinblastine (6 mg/m 2 , days 1 and 8) and Prednisolone (40 mg/m 2 , days 1–7) (CVP). The dose of cyclophosphamide in the CVP regimen is non‐toxic to the gonads and also reduces the potential of developing secondary leukaemia while the combination with vinblastine and prednisolone is both synergistic and efficacious (Sackmann‐Muriel et al , 1997). The preliminary results of this treatment approach have been very encouraging with excellent CR rates and survival outcome (Shankar et al , 2006).…”

Section: Discussionmentioning

confidence: 99%

Outcome of children with nodular lymphocyte predominant Hodgkin lymphoma – a Children's Cancer and Leukaemia Group report

et al. 2007

View full text Add to dashboard Cite

show abstract

“…Many clinicians have devised strategies to try to cure as many patients as possible despite the lack of key infrastructure at their center. For example, treatment of Hodgkin lymphoma and Wilms tumor without radiation therapy was first considered in PCUs without access to radiation therapy, and use of reduced doses of high‐dose methotrexate in ALL and non‐Hodgkin lymphoma regimens has been studied extensively in LMIC . In fact, these and other innovative strategies now used in HIC to minimize toxicity and optimize long‐term outcomes were pioneered in LMIC to address conditions that made the HIC regimen impractical in the local setting, including retinoblastoma staging, treatment of osteosarcoma without high‐dose methotrexate, and others …”

Section: Introductionmentioning

confidence: 99%

A framework to develop adapted treatment regimens to manage pediatric cancer in low‐ and middle‐income countries: The Pediatric Oncology in Developing Countries (PODC) Committee of the International Pediatric Oncology Society (SIOP)

Howard

Davidson

Luna‐Fineman

et al. 2017

Pediatric Blood & Cancer

Self Cite

View full text Add to dashboard Cite

Many children with cancer in low-and middle-income countries are treated in hospitals lacking key infrastructure, including diagnostic capabilities, imaging modalities, treatment components, supportive care, and personnel. Childhood cancer treatment regimens adapted to local conditions provide an opportunity to cure as many children as possible with the available resources, while working to improve services and supportive care. This paper from the Adapted Treatment Regimens Working Group of the Pediatric Oncology in Developing Countries committee of the International Society of Pediatric Oncology outlines the design, development, implementation, and evaluation of adapted regimens and specifies levels of services needed to deliver them.

show abstract

Hodgkin disease in children: Results of a prospective randomized trial in a single institution in Argentina

Cited by 5 publications

References 24 publications

Lymphome de Hodgkin de l’enfant: expérience de 24 ans au service d’hématologie à Casablanca, Maroc

Lymphome de Hodgkin de l’enfant: expérience de 24 ans au service d’hématologie à Casablanca, Maroc

Outcome of children with nodular lymphocyte predominant Hodgkin lymphoma – a Children's Cancer and Leukaemia Group report

A framework to develop adapted treatment regimens to manage pediatric cancer in low‐ and middle‐income countries: The Pediatric Oncology in Developing Countries (PODC) Committee of the International Pediatric Oncology Society (SIOP)

Contact Info

Product

Resources

About